Medipharm Labs Corp (LABS.TO) remains steady this week, holding its ground amidst a backdrop of recent developments in the cannabis sector.
Medipharm Labs Corp (LABS.TO) has seen a stable performance this week, with no significant changes in stock price. The latest closing price stands at C$0.07, reflecting a consistent trend in its valuation. As the company navigates the evolving landscape of the cannabis industry, investors are keenly observing its strategic moves and market positioning.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$29.90M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS · as of Sep 17, 2026
Wall Street analysts forecast LABS stock price to rise 42.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+42.9% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
72.4%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.07
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.06 – C$0.08 |
| 60 trading days | C$0.07 | C$0.05 – C$0.09 |
| 90 trading days | C$0.07 | C$0.05 – C$0.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Medipharm Labs continues to report steady stock performance, its recent financial results and strategic positioning within the U.S. pharmaceutical market could signal potential growth opportunities. Investors should monitor developments closely as the company aims to capitalize on emerging market trends.
Steady Performance Amidst Market Changes
Medipharm Labs has maintained a last close of C$0.07, with a 1-month decline of 6.67%, while trading volume has surged to 3.18 times its 20-day average.
Bull case
Medipharm Labs has reported an 8% annual revenue growth and a significant 43% increase in international medical cannabis revenue. This suggests a positive trajectory for the company's financial health. Additionally, the recent rescheduling of cannabis products by the U.S. Department of Justice positions the company well to meet increasing U.S. pharmaceutical demand.
Bear case
Despite its recent growth, Medipharm Labs faces challenges with a negative profit margin of -12.0% and a return on equity of -13.2%. The company’s stock has not shown significant price movement, indicating potential investor hesitance amid broader market uncertainties.
Price Action Overview
Medipharm Labs Corp (LABS.TO) has experienced a stable week, closing at C$0.07 with no change from the previous trading day. Over the past month, the stock has declined by 6.67%, while year-to-date performance remains unchanged. The stock's performance is being closely monitored by investors amidst a backdrop of strategic developments in the cannabis sector.
Recent Company News
Advertisement
While no major news has emerged this week, recent headlines have highlighted Medipharm's financial results for 2025, showcasing an annual revenue growth of 8% and a notable increase in international medical cannabis revenue. Additionally, the company's ability to capitalize on U.S. pharmaceutical demand due to recent regulatory changes is a focal point for future growth.
Technical Picture
From a technical standpoint, Medipharm Labs is currently trading at its 50-day moving average of C$0.07, which is 6.2% lower than the current price, and the 200-day moving average is also at C$0.07, showing a 3.4% decline. The stock has a 52-week range of C$0.06 to C$0.10, indicating it is currently positioned at 25% of its range. With a beta of 0.93, the stock exhibits slightly lower volatility compared to the broader market.
Insider Activity
No insider activity has been reported for Medipharm Labs Corp this week.
Final Price Action
As of the last close, Medipharm Labs Corp (LABS.TO) remains at C$0.07, with a 1D change of 0.00%. Investors will want to keep an eye on upcoming developments as the company continues to navigate the evolving cannabis landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
